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Objectives: Systemic antibiotic treatment of Lyme borreliosis is effective during the early stages of the infec-
tion, while chronic manifestations of the disease may remain refractory and difﬁcult to treat. This study was
carried out in order to evaluate the potential of topically applied azithromycin to eliminate the spirochaetal
organisms in the skin of the freshly bitten host and thereby prevent Lyme borreliosis.
Methods: Laboratory mice were challenged with Borrelia burgdorferi sensu stricto by needle inoculation or via
infected ticks as vectors. Then, an azithromycin-containing formulation was applied once daily to the sites of
exposure for three consecutive days. In the case of needle inoculation, a 5% azithromycin formulation was
applied starting 1 h, 3 days and 5 days after infection. In the case of tick exposure, 4%, 10% and 20%
azithromycin formulations were applied, starting directly after the detachment of the engorged ticks.
Subsequently, the infection status of the mice was determined.
Results: Concentrations of azithromycin in murine skin were .3800-fold higher than the published minimal
inhibitory concentration for B. burgdorferi as soon as 3 h after the ﬁrst application. After needle inoculation,
spirochaetes were not detectable in all infected mice after treatment, if the ﬁrst application started 1 h or
even after 3 days post-infection. Furthermore, no borrelial organisms were detected after topical treatment
when ticks were used for spirochaete inoculation.
Conclusions: Our data indicate that topical treatment with a formulation containing azithromycin is a promis-
ing approach to prevent Lyme borreliosis shortly after a tick bite.
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Introduction
Lyme borreliosis is caused by infection with different species of
the Borrelia burgdorferi sensu lato group that are transmitted
by Ixodes ticks.
1 Shortly after tick attachment, an increasing
number of spirochaetes around the site of the tick bite
may cause clinical signs of cutaneous inﬂammation and
B. burgdorferi organisms disseminate to distant locations of the
host’s body during the following stages of infection. In various
body sites, they can induce speciﬁc immune responses that
may result in chronic lesions due to inﬂammatory reactions.
2,3
Currently, the most recommended treatment regimen in the
early phase of infection is oral therapy with doxycycline or amoxi-
cillin for 10–20 days.
4 Without adequate treatment, months after
the onset of infection,  60% of patients experience prolonged clini-
cal signs and symptoms, especially arthritic episodes in the large
joints of the limbs and/or neurological abnormalities.
5 Indeed, anti-
biotic intervention leads to an effective clearing of the infection in
the early disease stages, but if treatment starts late (e.g. in the
chronic phase of infection)  10% of patients may experience
treatment-resistant symptoms of Lyme borreliosis.
5
A principal cause that leads to this chronic, in some cases
hardly manageable, disease is the difﬁcult diagnosis of Lyme
borreliosis in its early stages. Only 70%–80% of all human
patients develop an erythema migrans at the site of tick attach-
ment,
6,7 the early hallmark of an infection with B. burgdorferi.
5
Other non-speciﬁc clinical signs are generally fever, malaise,
headache, myalgia and arthralgia. Additionally, serological
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2814tests are often too insensitive and non-speciﬁc during the ﬁrst
1–2 weeks of infection.
8–10
These problems, which many patients and physicians encoun-
ter during the early stage of infection, and the lack of a licensed
vaccine for humans
5 necessitate other means of disease preven-
tion, e.g. a preventive therapeutic approach that clears the infec-
tion directly after removal of the feeding ticks. In fact, studies
focusing on antimicrobial therapy for the prevention of Lyme
borreliosis after exposure to Ixodes ticks have been performed
in humans, but most of them were not effective in controlled
treatment trials.
11–15 Promising results were published by
Nadelman et al.,
16 who showed statistically signiﬁcant preven-
tion of Lyme disease after tick bites by a single oral dose of
200 mg of doxycycline, when the drug was applied within 72 h
after removing attached Ixodes scapularis ticks. Based on this
investigation, the recommendation of such a prophylactic
approach was included in the Clinical Practice Guidelines of the
Infectious Diseases Society of America under deﬁned
circumstances.
4 The efﬁciency of doxycycline in preventing
Lyme borreliosis by a single oral dose was also documented in
a proof-of-concept study in mice.
17 Furthermore, the available
literature describing prophylactic approaches for preventing
Lyme borreliosis were reviewed recently by Warshafsky et al.
18
The summarized results of these reviewed clinical studies
showed that the relative risk for acquiring Lyme disease was
reduced by 91% in patients who had received antibiotic prophy-
lactic therapy. Additionally, the authors postulated that the
initiation of chemoprophylaxis soon after tick exposure is more
important than the application of different types of antibiotic
or varying treatment durations. However, all of these studies
used prophylactic approaches that were based on systemic anti-
biotic therapies. The disadvantages of these strategies are the
adverse effects documented for several patients, e.g. nausea
and vomiting caused by doxycycline or rashes resulting from
the use of amoxicillin and penicillin.
4,16,18 Besides, doxycycline
is contraindicated in pregnant woman and in children under
the age of 8 years.
4,16
Side effects due to the systemic application of antibiotics
should be limited or even absent when drug concentrations
are kept at a minimum. Experimental studies have shown that
B. burgdorferi organisms remain localized for .2 days in the
mammalian skin at the site of tick exposure, an area that is
just a few centimetres in diameter and can even be removed
by surgical means.
19 In this context, Shih et al.
20 showed that
infection can be effectively terminated by the topical application
of antibiotics (e.g. tetracycline hydrochlorides, penicillin G, amox-
icillin, ceftriaxone and doxycycline) directly on areas of tick bites
immediately after the detachment of I. scapularis nymphs
carrying B. burgdorferi organisms. Although the results were
promising, the authors recommended that this approach
should not be further evaluated for human use, because the
tested antibiotics had been dissolved in DMSO. The substance
was used as a carrier and is potentially harmful for humans.
20
The purpose of this study was to reconsider the feasibility of
treating Lyme borreliosis by a topical application of an antibiotic
on the area of tick exposure, and to evaluate the potential
effects of an ethanol-based azithromycin-containing formulation
for the prevention of infection and disease. Azithromycin was
selected because of its lower MIC for B. burgdorferi
(MIC≤0.015 mg/L) and fewer adverse effects when compared
with doxycycline (MIC≤0.25 mg/L).
4,21–23 In addition, azithro-
mycin (i) shows excellent tissue penetration, (ii) accumulates in
tissues, (iii) has a half-life of  5 days in tissues versus a few
hours in serum and (iv) does not leak into the circulation when
applied locally onto the skin. Consequently, mice were infected
with B. burgdorferi organisms using infected ticks or via needle
inoculation. Subsequently, animals were treated with the formu-
lation containing various doses of azithromycin or placebo. The
experiments demonstrated an efﬁcient prevention of infection
in all cases, if the treatment had started within 3 days post-tick
infection. Therefore, the tested formulation is a promising candi-
date for the prevention of B. burgdorferi infection when applied
topically and early on the site of tick exposure.
Materials and methods
Spirochaetes
Low-passage (passage 4) B. burgdorferi sensu stricto N40 (B. burgdorferi)
organisms that are an isolate from a skin punch biopsy of an
experimentally infected dog and that are infective for mice were used
for the needle inoculation.
24,25 Spirochaetes were cultured in modiﬁed
Barbour–Stoenner–Kelly (BSK II) medium at 338C.
Mice
The female C3H/HeN (C3H) mice used for the infection experiments were
bred by and purchased from Socie ´te Janvier, France. The mice were kept
under speciﬁc-pathogen-free conditions in individually ventilated cages
(Ehret, Berlin, Germany) at the animal facility of the Max Planck Institute
for Evolutionary Anthropology (Leipzig, Germany). For the assessment of
azithromycin concentrations in murine skin, 6-week-old female C3H mice
were bred by and purchased from Harlan Winkelmann GmbH, Borchen,
Germany. These mice were kept in ventilated cages at the animal facility
of the Institute of Infectious Diseases and Zoonoses, LMU Munich
(Munich, Germany). The animal experiments were carried out in accord-
ance with the guidelines approved by the Animal Care and Usage Com-
mittee of the Regierungspra ¨sidium Leipzig and the Sachgebiet
54-Tierschutz, Regierung von Oberbayern, Germany.
Infection by needle inoculation
Spirochaetes were grown to the late exponential phase. Forty C3H mice
were inoculated intradermally into their shaven backs with B. burgdorferi
(5×10
4 spirochaetes per mouse in a volume of 30 mL of BSK II medium).
Exposure to infected ticks
B. burgdorferi-infected ticks were bred by and purchased from
M. Matuscka and D. Richter (Charite ´ Berlin). Ticks were placed onto the
shaven backs of 38 mice (four to ﬁve ticks per mouse), protected by a
plastic capsule, for 96 h. During the complete period of tick attachment,
mice were caged individually. In cases that the capsule came off, the
cage litter was searched for removed ticks. Subsequently, in order to
measure the infection rate of ticks, all detached ticks were tested with
a quantitative real-time PCR (qPCR) for B. burgdorferi.
Topical treatment with the azithromycin-containing
formulations
The azithromycin formulations (containing 4%, 5%, 10% or 20% azithro-
mycin, polyacrylate, klucel and mygliol; 83.5%, 82.5%, 77.5% and 67.5%
of the volume was 94% ethanol, respectively) as well as the placebo
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volume was 94% ethanol) were kindly provided by Ixodes AG (Zu ¨rich,
Switzerland). In the case of needle inoculation, three groups of 10 mice
were treated with a formulation containing 5% azithromycin starting
1 h, 3 days and 5 days post-B. burgdorferi inoculation. Additionally, 10
mice received the placebo formulation (0% azithromycin) starting 1 h
post-inoculation. In the case of tick-borne inoculation, seven mice
received no formulation, nine mice were treated with placebo, nine
mice with a 4% azithromycin formulation, eight mice with a 10% azithro-
mycin formulation and ﬁve mice with a 20% azithromycin formulation.
Treatment started directly after tick detachment (96 h post-tick attach-
ment). In all cases, 200+3 mg of formulation were applied directly
onto the areas deﬁned by needle inoculation or tick attachment for
three consecutive days. This equates to a daily topical azithromycin
dose of 3.00+0.05 mg (4% formulation), 3.75+0.06 mg (5%),
7.50+0.11 mg (10%) and 15.00+0.23 mg (20%). During the treatment
period, the mice were caged individually.
Sera
Blood from all mice was obtained at day 56 post-tick detachment by
cardiac puncture. Serum was prepared in serum separators (BD Microtai-
ner; Becton Dickinson) by centrifugation (5000 g for 5 min, room temp-
erature). Sera were stored frozen at 2808C. For the calculation of ELISA
cut-offs, sera from four non-infected C3H/HeN mice served as negative
controls.
Tissue samples for cultivation and PCR
Skin biopsies from mice were collected aseptically 7, 14 and 28 days
post-needle inoculation or tick detachment from the same areas of pre-
vious spirochaetal exposure and were frozen at 2808C. In the case of
needle inoculation, an additional skin biopsy sample was collected on
day 28 post-inoculation for spirochaete detection in culture, as described
below. Mice were sacriﬁced on day 56 post-inoculation or tick detach-
ment. Tissues from the heart, skin from the right ear, right tarsal joint
and bladder were collected under sterile conditions. Tissue samples
were washed in 70% ethanol and in PBS. Whole bladder and joint, and
parts of ear and heart were squashed in 200 mL of BSK II. These tissue
mixtures were each individually transferred into 6 mL of sterile BSK II.
Tissue cultures were kept at 338C for 6 weeks and observed weekly for
the presence of viable spirochaetes by dark-ﬁeld microscopy.
Kinetic ELISA (KELA)
A computerized KELA was performed as described previously.
26
Sonicated whole-cell lysate of B. burgdorferi served as the antigen.
Murine sera were diluted 1:100 in PBS with 0.05% Tween
w 20 and 2%
milk powder (PBSTM). Borrelia-speciﬁc antibodies were detected with
horseradish peroxidase-conjugated goat antimouse IgG (R&D Systems,
Minneapolis, MN, USA) in a dilution of 1:1000 in PBSTM.
Western blotting
Western blot analysis of selected mice sera was performed with mem-
brane strips coated with Borrelia afzelii lysate antigen and recombinant
VlsE (B. afzelii+VlsE Eco Blot IgG Western Blot; Genzyme Virotech GmbH,
Ru ¨sselsheim, Germany). The test procedure was carried out according to
the manufacturer’s instructions. Alkaline phosphatase-conjugated
afﬁnity-puriﬁed goat antimouse IgG (Rockland Inc., Gilbertsville, PA, USA)
at a dilution of 1:4000 wasused asthe secondaryantibody. The substrate
reaction was stopped after 10 min. The interpretation of the test results
was performed according to included kit-speciﬁc protein band templates
and based on published criteria.
25,27,28
Quantiﬁcation of B. burgdorferi in ticks and skin biopsy
samples with a quantitative real-time PCR
The DNA of ticks and skin biopsies was extracted using a commercial kit
(DNeasy Blood & Tissue Kit; Qiagen, Hilden, Germany). The test procedure
was carried out according to the instructions supplied with the kit.
Extracted DNA from ticks was eluted in 50 mLo fH 2O and DNA from skin
biopsy samples was eluted in 200 mLo fH 2O. Ampliﬁcation of the 104 bp
ospA DNA target was performed with 2.5 mL of template DNA in a 25 mL
ﬁnal volume containing 1× reaction buffer (Invitrogen, Karlsruhe,
Germany), 20 U/mL Platinum Taq Polymerase (Invitrogen), 3.5 mM MgCl2
(Invitrogen), 900 nM of each oligonucleotide, 200 nM ﬂuorogenic probe
and 0.2 mM dNTPs. The oligonucleotide primers and probe were syn-
thesized by TibMolBiol GmbH (Berlin, Germany). The sequences used to
detect B. burgdorferi ospAwere: ospA-N40.seq-17F, 5′-AATGTTAGCAGCCTT
GACAGAA-3′; ospA-N40.seq-119R, 5′-GATCGTACTTGCCGTCTTTGTTT-3′; and
ospA-N40.seq-41T, 5′-FAM-AACAGCGTTTCAGTAGATTTGCCTGGTGA-TAMRA-
3′.
29All reactionsweretested intriplicate andthePCR was performed with
aLightCycler
w480(RocheDiagnosticsGmbH,Penzberg,Germany).ThePCR
was runfor2 min at 958C,and50 cyclesof15 sat958Cand30 sat 608C.A
standard curve for the quantiﬁcation of B. burgdorferi DNA was generated
by the addition of 10
7 spirochaetes to a skin biopsy sample of a naive
mouse. After DNA extraction, a dilution series was created from 10
7 to
10
0 spirochaete copies per biopsy.
For skin biopsies, the concentration of murine b-actin was determined
with the PCR conditions as described above. The sequences used to
detect murine b-actin were: b-actin-F, 5′-TCACCCACACTGTGCCCATC
TACGA-3′; b-actin-R, 5′-GGATGCCACAGGATTCCATACCCA-3′; and b-actin-
probe, 5′-Cy5-TATGCTCTCCCTCACGCCATCCTGCGT-BBQ-3′.
30
A titration series of extracted DNA derived from skin biopsies of naive
mice was used as a standard curve for murine b-actin. Based on the
b-actin quantiﬁcation, the detected copy numbers of B. burgdorferi
were normalized to 100 mg of mouse DNA.
Preparation of azithromycin standard dilutions for the
measurement of growth inhibition areas
Astandarddilutionserieswaspreparedtoassessthebacterialgrowthinhi-
bition induced by azithromycin. Micrococcus luteus (strain ATCC 4698;
DSMZ, Braunschweig, Germany) was grown in liquid Mueller–Hinton II
bouillon for 24 h at 378C on a rotating plate incubator. Bacterial growth
in the liquid media was measured spectrophotometrically (McFarland
standard 0.5). An aliquot of 100 mLo fM. luteus suspension was streaked
out on agar plates containing solid antibiotic medium no. 11 (AM 11;
Difco, Becton Dickinson GmbH, Heidelberg, Germany). Azithromycin-
containing dilutions (Fluka, Sigma–Aldrich, Munich, Germany) were pre-
pared in PBS ranging from 750 to 0.34 mg/L. Filter paper discs (Mast Diag-
nosticaGmbH,Rheinfeld,Germany)weresoaked individually with20 mLof
the azithromycin dilutions. Then, the discs were placed on AM 11 plates in
quadruplicate and incubated for 24 h at 378C. In addition, a commercial
standard positive-control disc (15 mg of azithromycin; Mast Diagnostica
GmbH, Rheinfeld, Germany) was also included in the assay. The growth
inhibition areas (diameters in mm) were measured after 24 h.
Measurement of azithromycin concentrations
in murine skin
Azithromycin concentrations in murine skin biopsy samples after the
application of a single dose of 5% azithromycin were determined with
a modiﬁed agar diffusion bioassay, as described by Bennett et al.
31 The
backs of all experimental mice were shaved ( 2.25 cm
2) and 200 mg
of a 5% azithromycin gel formulation was applied on this area. During
the next 24 h, the mice were kept individually. The mice were weighed
before and after the application of the formulation. Groups of three
Knauer et al.
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biopsy punch samples were collected from the shaven areas and
weighted. Then, skin samples were placed into 40 mL of sterile PBS. Biop-
sies were squeezed strongly with sterile pestles to release tissue ﬂuids.
Twenty microlitres of this solution was placed on ﬁlter paper discs and
growth inhibition areas were measured. Standard azithromycin dilutions
were prepared for each timepoint.
Statistics
Statistical analysis and graphic visualization of the results were
performed using the SigmaStat/SigmaPlot software (Systat Software
GmbH, Erkrath, Germany). When applicable, treatment groups were
compared using x
2 tests.
Results
The infection status of the animals was determined by culturing
B. burgdorferi organisms from skin and tissue samples, by detect-
ing B. burgdorferi-speciﬁc DNA in tissue with qPCR, and by
demonstrating speciﬁc antibodies against the infectious agent.
Azithromycin concentrations in skin after the application of the
antibiotic were assessed in a separate experimental approach.
Assessing azithromycin concentrations of skin biopsy
samples from needle-inoculated mice
Using a modiﬁed agar diffusion assay,
31 azithromycin concen-
trations in skin biopsy samples were measured 3, 6, 12 and
24 h after a single application of the supplied 5% azithromycin
formulation. Overall, the azithromycin concentrations in biopsy
samples ranged from 29.0 to .750 mg/L (Table S1; available
as Supplementary data at JAC Online). The published MIC of
azithromycin for B. burgdorferi is 0.015 mg/L.
22 Therefore,
azithromycin concentrations in skin biopsy samples taken from
the application site were up to .100000 times the MIC after
just a single treatment.
Measurement of B. burgdorferi DNA concentrations in
skin biopsy samples from needle-inoculated mice
In skin biopsy samples from all mice that had received the mock
treatment (0% azithromycin), ospA was detectable 7 days post-
inoculation. On day 14 post-inoculation, ospA was detected in
ﬁve biopsy samples of the placebo group and on day 28 post-
inoculation, biopsy samples from two mice were positive for
ospA in the placebo group (Table 1).
In contrast to the placebo group, no ospA was detectable in
biopsy samples collected from mice that had received the ﬁrst
application 1 h or 3 days post-inoculation, independent of the
timepoint of biopsy sampling, suggesting an efﬁcient elimination
of the spirochaetes in these groups. In mice that were treated
5 days post-inoculation, two biopsy skin samples collected on
day 8 post-inoculation were positive for ospA and one sample
collected on day 28 was ospA-positive (Table 1). Detailed
results of the PCR analyses are summarized in Table S2 (available
as Supplementary data at JAC Online).
Reisolation of spirochaetes from tissues
of needle-inoculated mice
Viable spirochaetes were reisolated from the inoculation site,
heart and urinary bladder of one mouse in the placebo group
(0% azithromycin). All tissues derived from the other animals of
this group as well as from the animals of the treatment groups
were culture-negative for B. burgdorferi organisms (Table 1).
Detailed results of the reisolation experiments are summarized
in Table S3 (available as Supplementary data at JAC Online).
IgG antibody responses against B. burgdorferi
after needle inoculation
Antibody levels of treated and untreated mice are shown in
Figure 1. High antibody levels were detected in 9 out of 10
mice that had received the placebo formulation (0% azithromy-
cin). In contrast, no B. burgdorferi-speciﬁc antibodies were
detectable in mice that had received the azithromycin formu-
lation also starting 1 h after inoculation. Groups of mice that
Table 1. Overall infection status of experimental mice that had received topical treatment with formulations containing 5% azithromycin starting
at varying timepoints after needle inoculation of B. burgdorferi by combining all available data: ospA real-time PCR, culture and serological
investigations
Concentration of azithromycin/
treatment start (%/time)
ospA PCR (skin biopsies)
Culture ELISA
Western
blot
Infection
status
7d a y s
post-inoculation
14 days
post-inoculation
28 days
post-inoculation
0/1 h post-inoculation 10/10
a 5/10 2/10 1/10 9/10 9/10 9/10
5/1 h post-inoculation 0/10 0/10 0/10 0/10 0/10 0/10 0/10
5/3 days post-inoculation 0/10 0/10 0/10 0/10 6/10 0/10 0/10
5/5 days post-inoculation 2/10
b 0/10 1/10 0/10 7/10 0/10 0/10
Differences between placebo and treatment groups were statistically highly signiﬁcant (P¼0.000; x
2 test).
aNumber positive/number tested.
bBiopsies were collected on day 8 instead of day 7 post-inoculation.
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post-needle inoculation) reacted heterogeneously. Elevated anti-
body levels were present in sera from 6 out of 10 mice that had
received the treatment starting 3 days post-inoculation and in 7
out of 10 mice that received the treatment starting 5 days
post-inoculation. It is noteworthy that the antibody levels in 10
seropositive animals, which were treated starting days 3 or 5
post-infection, were clearly lower than those found in animals
that had received the placebo treatment.
The results of the western blot analysis are shown in Figure 2.
Sera were considered positive for infection if signals were visible
for recombinant VlsE or at least two of the following bands: p83/
100; p58; p43; p39; p30; p23 (OspC); p21; and p17
(Osp17).
25,27,28Nine out of 10 mice that received the placebo for-
mulation were considered positive for an infection-speciﬁc
contact with borrelial antigen (Figure 2a). In contrast, mice
that had received treatment starting 1 h post-inoculation
(Figure 2b), 3 days post-inoculation (Figure 2c) and 5 days post-
inoculation (Figure 2d) were considered negative for infection.
Solely weak signals against OspA and OspC, which may have
been induced by antigen contact during the inoculation of
culture-adapted spirochaetes,
32 as well as weak non-speciﬁc
signals at 41 kDa (FlaB, p41) were detectable in these groups.
Infection with B. burgdorferi via ticks with subsequent
topical azithromycin treatment
Demonstration of B. burgdorferi DNA in murine skin biopsy
samples and ticks
Results of the PCR analyses are summarized in Table 2. Detailed
results of ospA detection in the skin and ticks are listed in Tables
S2 and S4 (available as Supplementary data at JAC Online).
Copies of the ospA gene were present in skin biopsies collected
from four out of seven mice that had received no treatment at
all and from three out of nine mice that had received the
placebo formulation. In general, skin biopsy samples were posi-
tive throughout the complete observation period (7, 14 and
28 days post-tick detachment), with the exception of one
mouse in which ospAwas detectable only on days 7 and 14 post-
tick detachment. No ospA genes were detectable in mice that
had received azithromycin-containing formulations, independent
of the azithromycin dose used. Notably, PCR analysis of the ticks
that were detached from the control mice that remained nega-
tive for B. burgdorferi infection revealed that these vectors con-
tained very low ospA copy numbers (≤1.0×10
2 ospA copies).
Such low bacterial burdens are considered insufﬁcient for host
infection.
Reisolation of spirochaetes after tick exposure
The results are summarized in Table 2 and listed completely in
Table S5 (available as Supplementary data at JAC Online).
Viable spirochaetes were reisolated only from mice that had
positive ospA skin biopsy samples throughout the complete
observation period (7, 14 and 28 days post-tick detachment).
All four PCR-positive animals that had received no treatment
carried viable B. burgdorferi organisms in all types of tested
tissues. The two animals that had received the placebo formu-
lation and were ospA-positive (PCR) on day 28 post-tick detach-
ment carried viable B. burgdorferi organisms in their ear tissues.
IgG antibody response to B. burgdorferi after tick exposure
The antibody responses of mice against borrelial antigens were
assessed on day 56 post-tick detachment using a KELA, as
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0% azithromycin 1 h post-inoculation
5% azithromycin 1 h post-inoculation
5% azithromycin 3 days post-inoculation
5% azithromycin 5 days post-inoculation
control sera (naive mice)
900
800
700
600
500
K
E
L
A
 
u
n
i
t
s
400
300
200
100
0
1 2 3 4 5 6 7 8 9
10
1 2 3 4 5 6 7 8 9
10
1 2 3 4 5 6 7 8 9
10
1 2 3 4 5 1 2 3 5 6 7 8 9
10
animal
Figure 1. IgG antibody levels in C3H mice 56 days post-needle inoculation of B. burgdorferi. Mice were inoculated intradermally with 5×10
4
B. burgdorferi organisms and treated 1 h, 3 days or 5 days after the inoculation. Error bars represent standard deviations of duplicates.
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animals that were positive in tissue cultures contained speciﬁc
antibodies against B. burgdorferi. However, speciﬁc antibodies
were absent in animals that were not treated or had received
the placebo formulation and concurrently showed no ospA
signals in their biopsy samples (PCR) on day 28 post-tick detach-
ment. All animals that had received the azithromycin-containing
formulations failed to produce speciﬁc antibodies.
0% azithromycin 5% azithromycin
(a) (b) (c) (d)
M 12345678910 1 2345678910 123 456 78910 123 456 78910
Figure 2. Western blot analysis of murine serum samples 56 days post-needle inoculation of B. burgdorferi. Placebo or topical azithromycin were
applied 1 h (a and b), 3 days (c) or 5 days (d) post-inoculation. M, positive-control marker for protein bands.
Table 2. Overall infection status of experimental mice that had received topical treatment with formulations containing varying concentrations of
azithromycin starting immediately after tick detachment by combining all available data: ospA real-time PCR, culture and serological investigations
Concentration of
azithromycin
ospA PCR (skin biopsy samples)
Culture ELISA
Infection
status
7 days post-tick
detachment
14 days post-tick
detachment
28 days post-tick
detachment
No treatment 4/7
a 4/7 4/7 4/7 4/7 4/7
0% (placebo) 3/9 3/9 2/9 2/9 2/9 2/9
4% 0/9 0/9 0/9 0/9 0/9 0/9
10% 0/8 0/8 0/8 0/8 0/8 0/8
20% 0/5 0/5 0/5 0/5 0/5 0/5
Differences between all groups were signiﬁcant (P¼0.009; x
2 test). Comparison of the two control groups (no treatment versus placebo) revealed no
signiﬁcant differences (P¼0.152; x
2 test). Control groups (no treatment combined with placebo) versus all treatment groups differed signiﬁcantly
(P¼0.001; x
2 test).
aNumber positive/number tested.
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JACDiscussion
The aim of this study was to evaluate the efﬁcacy of an
azithromycin-containing formulation for the prevention of infec-
tion with B. burgdorferi and probably other species belonging to
the B. burgdorferi sensu lato complex.
This hypothesis of preventing B. burgdorferi infection and, con-
sequently, disease by applying topical azithromycin was tested in
a murine model based on two different routes of bacterial inocu-
lation: (i) needle inoculation of a deﬁned dose of B. burgdorferi
with subsequent topical application of 5% azithromycin or
placebo starting 1 h, 3 days or 5 days post-inoculation; and (ii)
spirochaete infection induced with experimentally infected ticks
as vectors with subsequent topical application of 0%, 4%, 10%
and 20% azithromycin formulation starting immediately after
tick detachment.
In general, borrelial inoculation in mice by either needle
inoculation or tick exposure was successful, since infected mice
were present in both groups. Single tick-exposed control mice
(receiving no treatment or placebo treatment) were considered
negative for infection when tested at the end of the observation
period. However, PCR testing of ticks, which had been detached
from these animals, demonstrated spirochaetal burden
(Table S4 available as Supplementary data at JAC Online). The
numbers of organisms per tested tick, which we determined
using PCR, were lower than the doses considered to be necessary
for the successful infection of mice.
33,34 Nevertheless, the other
placebo-treated control mice became infected when they were
exposed to ticks carrying sufﬁcient bacteria. Topical application
of the placebo formulation had no impact on the survival of
the Borrelia organisms and on the following immune response
of the host. In contrast to the control animals, none of the
azithromycin-treated mice that were exposed to the ticks,
which contained sufﬁcient bacteria for infection, showed evi-
dence of infection with B. burgdorferi even after an observation
time of 56 days. Furthermore, no evidence of infection was
found in needle-inoculated and subsequently azithromycin-
treated animals when topical treatment was delayed for
3 days post-inoculation. Therefore, we speculate that the
applied azithromycin formulation is highly efﬁcient in reducing
local B. burgdorferi burden, even if the treatment starts late
(3 days post-infection). Speciﬁc antibodies that were detected
with western blots in several animals, which had received the
delayed treatment, were predominately directed against the
outer surface proteins OspA and OspC. OspA is commonly
up-regulated by B. burgdorferi in questing ticks or when the spir-
ochaetes are cultured in medium.
35 Therefore, it is likely that the
signals seen on our blots were remnant signals of inoculated,
culture-derived spirochaetes, as described previously.
32 When
B. burgdorferi organisms are transmitted by ticks, delivery of
the bacteria into the skin of the host starts  24–48 h after
tick attachment.
36 In our experimental setting, spirochaetes
transmitted via tick exposure should have been present in the
mice’s skin for several days, especially at the time when the anti-
biotic was applied topically 3 days after tick attachment. In con-
trast to needle inoculation, the failure to produce speciﬁc
antibodies by these animals could be the result of an immune
suppressive effect induced by the tick saliva. Consequently, the
production of detectable levels of antibodies, which in the
course of B. burgdorferi infection occurs weeks after the start
of infection,
25 probably was suppressed initially. In the further
course of our experiment, spirochaetes were killed as expected
500
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Figure 3. IgG antibody levels in C3H mice 56 days post-detachment of B. burgdorferi infected ticks. Error bars represent standard deviations of
duplicates.
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2820by azithromycin, were removed and the adaptive immune
system failed to initiate an appropriate response.
The infection rates of mice that had received treatment start-
ing 5 days after tick detachment require careful consideration.
Serological data as well as our culture results suggest that
initial infections were cleared. Positive PCR signals in two mice
7 days after inoculation and, even more importantly, in one
animal 28 days post-inoculation imply the presence of non-
culturable spirochaetes in these cases.
37–39 It was shown that
B. burgdorferi remains localized for .2 days at the site of infec-
tion before the organisms start to disseminate.
19 Therefore, it
is plausible that a treatment starting 5 days after inoculation is
too late for clearing the early infection. Nevertheless, topical
azithromycin treatment starting immediately or up to 3 days
post-Borrelia inoculation seems to be able to abort the infection.
Our results are in accordance with those produced by Shih
et al.,
20 who tested the topical application of penicillin G, amox-
icillin, ceftriaxone and doxycycline after tick detachment. These
authors conﬁrmed efﬁcient clearing of B. burgdorferi organisms
when treatment started up to 2 days post-tick detachment.
20
In contrast to Shih et al.,
20 we used an antibiotic from the
macrolide group (azithromycin) to fend off B. burgdorferi organ-
isms. Azithromycin was chosen because of its high efﬁcacy
against B. burgdorferi
22,40,41 and its known repository effect.
This assumption was conﬁrmed when we measured the azithro-
mycin concentrations in murine skin, which were .3800 times
higher than the published MIC. This suggests that the killing of
spirochaetes localized in the skin is possible. Moreover, ethanol
was used instead of DMSO as a solvent ingredient in the
formulation used for this study. This is a prerequisite for this
formulation to ﬁnd its way into clinical practice. Blood levels of
azithromycin in the mice were not determined, because the
aim of the current study was to test the proof of concept. Like-
wise, the efﬁcacy of the azithromycin-containing formulation
against other pathogenic Borrelia species, such as B. afzelii or
Borrelia garinii, was not tested in our model. However, several
publications suggest that these species are susceptible to
azithromycin as well.
22,40
In summary, our data suggest that topical treatment with an
azithromycin-containing formulation shortly after tick exposure
and attachment can stop and effectively clear a B. burgdorferi
infection. Considering common side effects linked to antibiotics,
this approach seems to be beneﬁcial when compared with stan-
dard antibiotic therapies, which are applied systemically. Drug
concentrations are kept extremely low, so side effects are
avoided or minimized. Treatment starts at a timepoint when
the infection is very treatable,
4,42and spirochaetal dissemination
and, consequently, persistent infection can be prevented.
However, clinical studies in humans using the azithromycin-
containing formulation are necessary to adapt the antibiotic
concentration to the conditions necessary for human skin and
clarify the pharmacokinetics of azithromycin after topical
application.
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